Human clinical trials are under way for a U.S. drug to treat Alzheimer's disease, based on the design of a Purdue University researcher.
"Current drugs manage the symptoms, but this could be the first disease-modifying therapy," said Professor Arun Ghosh. "It may be able to prevent and reverse the disease."
Ghosh and Jordan Tang of the Oklahoma Medical Research Foundation developed the drug CTS-21166.
In 2000, Tang identified beta-secretase, a key enzyme in the progression of Alzheimer's that triggers the formation of amyloid plaques in the brain. Ghosh later built a molecule that binds to the enzyme and inhibits its activity.
"These molecules fit together like puzzle pieces," Ghosh said. "We created a molecule that fits with a key piece of the Alzheimer's disease puzzle. When the treatment molecule binds to the enzyme, it changes the shape of that puzzle piece so that it no longer fits in its original spot. This halts the chain reaction that leads to the devastating symptoms of Alzheimer's disease."
Ghosh reports his recent work in the May 17 issue of the Journal of Medicinal Chemistry.
Copyright 2007 by United Press International
Related stories:
Linking 2 molecular pieces of the Alzheimer's puzzle
Researchers have uncovered a biological link between the protein whose mutation causes early-onset Alzheimer’s disease (AD) and a gene variant linked to late-onset AD. The researchers said their finding could lead to new approaches to treating AD.
Scientists demonstrate means of reducing Alzheimer's-like plaques in fly brain
Neuroscientists at Cold Spring Harbor Laboratory (CSHL) are part of a collaboration that has succeeded in demonstrating that overexpression of an enzyme in the brain can reduce telltale deposits causally linked with Alzheimer's disease.
Researchers explore the emerging role of infection in Alzheimer's disease
The realization that pathogens can produce slowly progressive chronic diseases has opened new lines of research into Alzheimer's disease. In a special issue of the
Journal of Alzheimer's Disease published May 2008, guest editors Judith Miklossy, from the University of British Columbia, and Ralph N. Martins, from Edith Cowan University and Hollywood Private Hospital, Perth, Western Australia, and a group of experts explore this exciting topic.
Model shows how mutation tips biochemistry to cause Alzheimer's
Your fate can be determined by tiny events. Imagine you live in the city and you walk everywhere to get exercise – you are healthy and not afraid of getting mugged. You almost never eat breakfast so you don’t stop at the donut shop on the way to work, until one day the manager replaces the girl at the counter with her pretty red-haired younger sister. This seemingly unimportant change in your world is just enough to overcome your ability to resist high-fat temptation. A million donuts later, your cholesterol level surges and then your heart gives out. Curse you, little red-haired girl!
Researchers discover new link to schizophrenia
Neuroscientists at Johns Hopkins have discovered that mice lacking an enzyme that contributes to Alzheimer disease exhibit a number of schizophrenia-like behaviors. The finding raises the possibility that this enzyme may participate in the development of schizophrenia and related psychiatric disorders and therefore may provide a new target for developing therapies.
Scientists discover compound that could lead to new blood pressure drugs
University of Florida researchers have identified a drug compound that dramatically lowers blood pressure, improves heart function and — in a remarkable finding — prevents damage to the heart and kidneys in rats with persistent hypertension.
Pin1 is beneficial in Alzheimer's disease, detrimental to some forms of dementia
The most common form of dementia, Alzheimer’s disease, and a relatively rare hereditary form of dementia, frontotemporal dementia with parkinsonism-17, share a common pathology: Both are the result of an overaccumulation of tau proteins, which form tangled lesions in the brain’s neurons and eventually lead to the collapse of the brain cells responsible for memory. And, although mutations in the gene encoding tau have not been found in individuals with Alzheimer’s disease, they have been identified in individual with frontotemporal dementia, and are often used as models for studying Alzheimer’s disease.
Alzheimer's vaccine clears plaque but has little effect on learning and memory impairment
A promising vaccine being tested for Alzheimer's disease does what it is designed to do -- clear beta-amyloid plaques from the brain -- but it does not seem to help restore lost learning and memory abilities, according to a University of California, Irvine study.